The emergence of new cannabis derivatives such as HHC, HHCO, and HHCP has sent shockwaves through the cannabinoid world. Their growing popularity among consumers seeking legal alternatives to THC quickly attracted the attention of French health authorities. Faced with the increasing use of these products, their sale and consumption were banned in France, raising numerous questions about their psychoactive effects, regulatory status, and associated risks. This article explains the reasons and legal framework behind this ban.
What are HHC, HHCO and HHCP?
HHC, HHCO, and HHCP all belong to the cannabinoid. Unlike natural compounds such as CBD or THC, they are distinguished by their chemical structure and method of extraction. Although they are considered cannabis derivatives, their origin raises questions about their safety.
HHC (hexahydrocannabinol), HHCO (hexahydrocannabinol acetate) , and HHCP (hexahydrocannabiphorol) are designed to mimic some of the effects of THC. However, they are most often synthetic molecules, resulting from chemical transformations of natural hemp extracts. This fundamental distinction is already raising serious regulatory and public health.
Psychoactive effects and associated risks
One of the main reasons for the ban on these substances in France is related to their effects being similar to THC , the main psychoactive compound in cannabis. HHC, HHCO, and HHCP induce altered states of consciousness, sometimes more intense or unpredictable, due to their potency or method of manufacture .
The similarity to THC isn't limited to the euphoria sought by some users. Several reports describeside effects such as tremors, vomiting, episodes ofacute anxiety, bad trips , and mental confusion. These worrying symptoms directly contribute to the risk of abuse and addiction, which is of particular concern to health authorities. To gain a deeper understanding of current regulations, a detailed look at theANSM's ban on THCP provides a clearer picture of the measures recently taken against these synthetic cannabinoids.
Limited data on security
It remains difficult to accurately assess the extent of the danger when few rigorous studies analyze the medium- or long-term toxicity of these molecules. Unlike natural THC , which has been studied extensively, these new cannabis derivatives suffer from a real lack of scientific data. This uncertainty leads health agencies to apply the precautionary principle to synthetic molecules that are still poorly understood.
The reported incidents involve both physical and psychological. Some people report cardiac or neurological problems, increasing the vigilance of French legislators regarding these products.
A significant potential for addiction
These new substances also present a significant addictive potential. Like other cannabinoids with potent effects, they act on the pleasure and reinforcement circuits, thus increasing the risk of abuse and dependence, particularly among young people or vulnerable populations.
The total lack ofregulation on the purity or concentration of these products promotes the circulation of cut or overdosed substances, further aggravating the health consequences and multiplying risky behaviors.
The legal framework in France
Theban on HHC, HHCO, and HHCP in France stems directly from a desire to protect the population from new molecules whose effects remain largely unknown. Their classification as narcotics results from analyses conducted by bodies such as theNational Agency for the Safety of Medicines and Health Products (ANSM).
Upon their arrival on the market, the authorities chose toact swiftly. This strategy aims to limit the spread of these substances, anticipating both their potential for abuse and possible circumvention of regulations on traditional cannabis. The lack oftransparency surrounding the production methods of these cannabinoids has only reinforced the firmness of the French approach. To understand how these bans take effect and are disseminated within the sector, you can consult a dedicated section on theofficial prohibition of several chemical cannabinoids.
How does the ANSM's decision-making process work?
TheANSM ( ) has the power to provide expertise and make recommendations on all substances that pose a risk to public health or that could be misused for recreational purposes. It relies on feedback from healthcare professionals, analyses from toxicological laboratories, and the observation of emerging trends.
When a proven or suspected risk is identified, even without a major incident reported, the substance classified as a narcotic . This automatically entails aban on its manufacture, import, sale, and consumption throughout France.
Biological and legal similarity to THC
At the molecular level, these new compounds exhibit a marked similarity to THC, sufficient to generate similar psychoactive effects. This similarity facilitates rapid absorption by the nervous system, justifying the stringency of the regulatory framework in place.
This criterion implies that any molecule that can imitate or exceed the action of THC almost automatically enters the list of illicit drugs, thus ensuring harmonization of health control with regard to cannabis products.
Consequences of the ban on the French market
The application of French law brings about immediate changes to the availability of these controversial molecules. Online sales, once flourishing thanks to legal loopholes and the speed of e-commerce, now become subject to criminal prosecution as soon as the official decree is published.
Specialized retailers must immediately remove all goods containing HHC, HHCO, or HHCP, under penalty of severe sanctions. Stocks are destroyed or sealed. For consumers, access to these products disappears abruptly, often without clear information about the risks previously associated with them.
- Immediate removal of the offending items from physical stores and online shops
- Legal risks for users and sellers
- Fluctuation and then cessation of supply on the black market
- Substitution phenomenon towards other molecules or forms of synthetic cannabinoids
- Deterrent effect on the experimentation of new products
The agility of the illegal market sometimes makes it difficult to monitor successive bans. Hence the need, regularly reiterated by public authorities, to accompany each new ban with targeted communication on the dangers associated with these artificial alternatives.
Frequently asked questions about HHC, HHCO, HHCP and their status in France
What are the most common side effects associated with the consumption of HHC, HHCO or HHCP?
- Anxiety and bad trip episodes
- Body tremors
- vomiting and nausea
- Mental confusion and disorientation
For some people, consuming these synthetic molecules also leads to cardiovascular problems, palpitations, and paranoid episodes. Side effects vary depending on the individual, the dose, and the purity of the product used.
Why does France classify these molecules as narcotics?
The classification as a narcotic is based on several criteria:
- Similar to THC in terms of psychoactive effects
- Lack of reliable long-term safety studies
- Reported cases of risk of abuse and addiction
- Synthetic molecule that is difficult to control
Such regulations aim to reduce the spread of substances that pose a potential health risk, while maintaining the strict legal framework around cannabis and its derivatives.
Can these cannabinoids still be bought or consumed in France?
No, since the ANSM's decision, the sale and consumption of HHC, HHCO, and HHCP are prohibited. Any violation is punishable by law, ranging from fines to imprisonment. Shops, including online stores, are no longer allowed to offer them.
| Product | Status in France |
|---|---|
| HHC | Forbidden |
| HHCO | Forbidden |
| HHCP | Forbidden |
Obtaining these products, even from foreign sources, remains illegal on French territory.
What are the differences between these molecules and legal CBD?
- CBD soothe without causingsignificant psychoactive effects, unlike the substances mentioned.
- CBD is not classified as a narcotic as long as its THC content respects the legal limit
- CBD has benefited from extensive studies attesting to its relative safety in adults, whereas HHC, HHCO and HHCP lack solid scientific literature.
Other derivatives of synthetic cannabis therefore struggle to offer the same level of confidence to users and health authorities.
Editor-in-Chief specializing in CBD
Julien, born on July 17, 1978, in the Paris region, is a prominent writer and expert in the field of CBD products. Following his studies, Julien developed a passion for natural remedies, including CBD. In 2022, he joined the CBD.fr team as an expert and regular contributor. Thanks to his scientific expertise and clear writing style, Julien helps demystify the complexities of CBD, while highlighting its benefits and potential applications through his articles and conference presentations.
